

FORM PTO-1390 (REV. 9-2001)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER SPO-116	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371				U.S. APPLICATION NO. (If known, see 37 CFR 1.5)	
				10/070569	
INTERNATIONAL APPLICATION NO. PCT/JP00/06147		INTERNATIONAL FILING DATE 08 September 2000		PRIORITY DATE CLAIMED 10 September 1999	
TITLE OF INVENTION EARLY CANCER TUMOR MARKER					
APPLICANT(S) FOR DO/EO/US Takashi Muramatsu, Kohji Okamoto, Shinya Ikematsu, Munehiro Oda, Hideshi Kumai, Sadatoshi Sakuma					
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:					
<p>1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.</p> <p>2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.</p> <p>3. <input type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.</p> <p>4. <input type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (Article 31).</p> <p>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))</p> <p>a. <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau).</p> <p>b. <input checked="" type="checkbox"/> has been communicated by the International Bureau.</p> <p>c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</p> <p>6. <input checked="" type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).</p> <p>a. <input checked="" type="checkbox"/> is attached hereto.</p> <p>b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4).</p> <p>7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))</p> <p>a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau).</p> <p>b. <input type="checkbox"/> have been communicated by the International Bureau.</p> <p>c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</p> <p>d. <input type="checkbox"/> have not been made and will not be made.</p> <p>8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).</p> <p>9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)) <u>unsigned</u></p> <p>10. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</p> <p>Items 11 to 20 below concern document(s) or information included:</p> <p>11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</p> <p>12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</p> <p>13. <input checked="" type="checkbox"/> A FIRST preliminary amendment.</p> <p>14. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.</p> <p>15. <input type="checkbox"/> A substitute specification.</p> <p>16. <input type="checkbox"/> A change of power of attorney and/or address letter.</p> <p>17. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825.</p> <p>18. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4).</p> <p>19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).</p> <p>20. <input checked="" type="checkbox"/> Other items or information: Certificate of Mailing by Express Mail</p>					

U.S. APPLICATION NO. 10/070569 INTERNATIONAL APPLICATION NO. PCT/JP00/06147		ATTORNEY'S DOCKET NUMBER SPO-116	
21. <input checked="" type="checkbox"/> The following fees are submitted: BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)): Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO. \$1040.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$890.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$740.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$710.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00 ENTER APPROPRIATE BASIC FEE AMOUNT =		CALCULATIONS PTO USE ONLY <div style="border: 1px solid black; padding: 5px; width: fit-content; margin: auto;">\$890.00</div>	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).			
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE
Total claims	14 - 20 =	0	x \$18.00
Independent claims	5 - 3 =	2	x \$84.00
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$270.00
TOTAL OF ABOVE CALCULATIONS =			\$1,058.00
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.			+ \$529.00
SUBTOTAL =			\$529.00
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).			
TOTAL NATIONAL FEE =			\$529.00
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +			
TOTAL FEES ENCLOSED =			\$529.00
			Amount to be refunded: \$
			charged: \$
a. <input type="checkbox"/> A check in the amount of \$ _____ to cover the above fees is enclosed. b. <input checked="" type="checkbox"/> Please charge my Deposit Account No. <u>19-0065</u> in the amount of \$ <u>529.00</u> to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>19-0065</u> . A duplicate copy of this sheet is enclosed. d. <input type="checkbox"/> Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.			
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.			
CORRESPONDENCE ADDRESS:			
CUSTOMER NUMBER 23,557		March 8, 2002 DATE	
		David R. Saliwanchik SIGNATURE	
		David R. Saliwanchik NAME	
		31,794 REGISTRATION NUMBER	

March 8, 2002

Patent Application
Docket No. SPO-116

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Takashi Muramatsu, Kohji Okamoto, Shinya Ikematsu, Munehiro Oda,
Hideshi Kumai, Sadatoshi Sakuma

Docket No. : SPO-116

For : Early Cancer Tumor Marker

PRELIMINARY AMENDMENT

Please amend the above-identified patent application as follows:

In the Specification

Please add the following paragraph at page 1, above line 5:

This application is a National Stage Application of International Application
Number PCT/JP00/06147, published, pursuant to PCT Article 21(2).

Please substitute the following paragraph at page 9, lines 15-25:

In another embodiment, MK can be used as a marker for certain types of cancers, such as hepatocellular carcinoma. Blood MK level rises with the advancement of the stage of hepatocellular carcinoma. For cancer diagnosis, the assay described above is performed multiple times sequentially, and the change in MK level is evaluated. For example, this assay is

performed over six months to a year, every twenty-four to seventy-two hours, and is performed thereafter as necessary. Generally, cancer is progressing in patients whose MK value, as detected by antibodies, is increasing sequentially.

Please substitute the following paragraph at page 14, lines 19-24:

Specifically, for rabbits, 400 µg MK containing solution mixed with an equivalent amount of Freund's complete adjuvant was initially injected subcutaneously, and from the second time and onwards, 400 µg MK containing solution mixed with an equivalent amount of Freund's incomplete adjuvant was injected each time subcutaneously. For chickens, the procedure was similar to that of rabbits, except that 100 µg MK was used each time for injections.

In the claims

Claim 1 (amended):

A method for detecting early cancer, comprising the steps of:

- a) measuring the level of midkine, a fragment thereof, or both in a biological sample, and,
- b) comparing the measured level obtained in step a) to a control midkine level of a healthy subject, wherein an elevated measured level as compared to the control level indicates the presence of early cancer.

Claim 9 (amended):

A method for detecting early cancer comprising the steps of (a) contacting a biological sample with an antibody that specifically binds to midkine, a fragment thereof, or both, and (b)

comparing the level of binding between the antibody and midkine, a fragment thereof, or both of step (a) to a control binding level of a healthy subject, wherein an elevated binding level as compared to the control level indicates the presence of early cancer.

Claim 10 (amended):

A diagnostic agent for early cancer comprising an antibody that recognizes midkine, a fragment thereof, or both.

Claim 11 (amended):

A kit for detecting early cancer in a biological sample, wherein (a) the kit comprises a container that holds an antibody that specifically binds to at least one epitope of midkine, a fragment thereof, or both and (b) the antibody determines the presence of midkine, a fragment thereof, or both in the biological sample.

Claim 13 (amended):

A method for assessing cancer prognosis, comprising the steps of:

- a) measuring the level of midkine, a fragment thereof, or both in a biological sample, and,
- b) correlating the measured level obtained from step a) to cancer prognosis, to thereby assess cancer prognosis.

Claims 1, 9-11 and 13 have been amended. No new matter has been added by these amendments.

The Commissioner is hereby authorized to charge any fees under 37 CFR 1.16 or 1.17 as required by this paper to Deposit Account 19-0065.

Respectfully Submitted



David R. Saliwanchik

Patent Attorney

Registration No. 31,794

Phone No.: 352-375-8100

Address: Saliwanchik, Lloyd & Saliwanchik
2421 N.W. 41st Street
Suite A-1 Gainesville, FL 32606

DRS/la

Marked-up Version of Substituted Paragraphs

Please substitute the following paragraph at page 9, lines 15-25:

In another embodiment, MK can be used as a marker for certain types of cancers, such as hepatocellular carcinoma. Blood MK level rises with the advancement of the stage of hepatocellular carcinoma. For cancer diagnosis, the assay described above is performed multiple times sequentially[(over time)], and the change in MK level is evaluated. For example, this assay is performed over six months to a year, every twenty-four to seventy-two hours, and is performed thereafter as necessary. Generally, cancer is progressing in patients whose MK value, as detected by antibodies, is increasing sequentially[over time].

Please substitute the following paragraph at page 14, lines 19-24:

Specifically, for rabbits, 400 µg MK containing solution mixed with an equivalent amount of Freund's complete adjuvant was initially injected subcutaneously, and from the second time and onwards, 400 µg MK containing solution mixed with an equivalent amount of Freund's incomplete adjuvant was injected each time subcutaneously. For chickens, the procedure was similar to that of rabbits, except that 100 µg MK was used each time for injections.

Marked-up Version of Substituted ClaimsClaim 1 (amended):

A method for detecting early cancer, comprising the steps of:

- a) measuring the level of midkine, [and/or] a fragment thereof, or both in a biological sample, and,
- b) comparing the measured level obtained in step a) to a [measured level]control midkine level of a healthy subject, wherein an elevated measured level as compared to the control level indicates the presence of early cancer.

Claim 9 (amended):

[A use of] A method for detecting early cancer comprising the steps of (a) contacting a biological sample with an antibody [recognizing]that specifically binds to midkine, [and/or] a fragment thereof, or both [for early cancer detection], and (b) comparing the level of binding between the antibody and midkine, a fragment thereof, or both of step (a) to a control binding level of a healthy subject, wherein an elevated binding level as compared to the control level indicates the presence of early cancer.

Claim 10 (amended):

A diagnostic agent for early cancer comprising an antibody that recognizes midkine, [and/or] a fragment thereof, or both.

Claim 11 (amended):

A kit for detecting early cancer in a biological sample, wherein (a) the kit ~~[(a)]~~ comprises a container that holds an antibody that specifically binds to at least one epitope of midkine, [and/or] a fragment thereof, or both and (b) the antibody determines the presence of midkine, [and/or] a fragment thereof, or both in the biological sample.

Claim 13 (amended):

A method for assessing cancer prognosis, comprising the steps of:

a) measuring the level of midkine, [and/or] a fragment thereof, or both in a biological sample, and,

b) correlating the measured level obtained from step a) to cancer prognosis, to thereby assess cancer prognosis.

DESCRIPTION**EARLY CANCER TUMOR MARKER**5 Technical Field

This invention relates to a tumor marker for detecting early cancers.

Background Art

10 The degree of cancer progression or enlargement is described as early cancer, advanced cancer, and terminal cancer. Among them, early cancer is generally considered as "a degree of cancer progression in which the tumor is small, shows few metastases, and can be cured permanently or the cancer can be subdued for a long
15 time through treatment".

Early cancer is basically symptomless. Therefore, symptomless subjects are the targets who are tested when trying to nearly completely detect early cancer. Tests targeting a broad range of symptomless subjects to find patients affected by a
20 particular disease, or to narrow down the subjects to those requiring advanced secondary tests, are generally called screening. Generally, in screening, the number of test subjects is extremely large. In order to test many subjects, the screening should first and foremost be convenient and economical. Although testing for
25 tumor markers is a favorable testing method with little invasion of patients, currently, detection of early cancer by measuring tumor markers is considered impossible.

Midkine (hereinafter, referred to as "MK") is a proliferation and differentiation factor that was discovered as a retinoic
30 acid-responsive gene product, and is a 13-kDa polypeptide rich in basic amino acids and cysteines (Kadomatsu, K. et al.: Biochem. Biophys. Res. Commun., 151: 1312-1318; Tomomura, M. et al.: J. Biol. Chem., 265: 10765-10770, 1990). The fact that the MK level is elevated in various malignant tumors compared to the surrounding
35 normal tissues, suggests that MK plays an important role in carcinogenesis. Consequently, diagnosis of cancer by Northern

blotting using MK gene as a probe (Unexamined Published Japanese Patent Application No. (JP-A) Hei 6-113898) and a diagnostic agent for cancer containing anti-MK protein antibody (JP-A Hei 6-172218) have been suggested. However, these published patent applications do not describe nor suggest that MK genes or MK proteins are useful in early cancer detection. Thereafter, Ye et al. have reported that MK expression is elevated in pre-cancerous tissues at adenoma stages of human colorectal cancer (Ye C. et al.: Br. J Cancer., 79: 179-183, 1999). However, there is no description or suggestion in this report regarding early cancer detection.

Therefore, the discovery of tumor markers that may be detected from early cancer conditions and the development of tests for detecting such markers have been anticipated.

Disclosure of the Invention

An objective of the present invention is to provide a novel polypeptide useful as an early cancer marker. In addition, another objective of the present invention is to provide a method for detecting early cancer using this polypeptide as an index. Furthermore, another objective of the present invention is to provide an external diagnostic agent for early cancer that can detect this polypeptide.

The present inventors found that MK levels detected by anti-MK antibodies in hepatocellular carcinoma patients were significantly enhanced at the early stage of hepatocellular carcinoma, not only in hepatocellular carcinoma tissues, but also in the blood and urine compared to healthy subjects or hepatitis patients. Even in gastric cancer, MK levels in the blood and urine were found to be significantly elevated at the early stage, similar to hepatic cancer. Furthermore, in many types of cancers, such as esophageal, duodenal, colon, bile duct and gallbladder, pancreatic, thyroid, lung, and breast cancers, significant elevation of serum MK levels was observed in their early stages. This indicates that MK has an extremely wide spectrum of specificity that is not seen in well-known tumor markers for detecting unspecified cancers.

According to these findings, the present inventors elucidated

the utility of MK as an early cancer marker. Furthermore, a screening diagnosis of early cancer was made possible through the highly sensitive detection of MK levels appearing in the body fluid of patients at an early stage of various cancers using a simple and highly sensitive one-step sandwich method developed by the present inventors that utilizes an enzyme immuno assay (EIA). EIA can be completely automated and is extremely useful as a method for measuring MK that aims at early cancer detection.

That is, the present invention relates to a method for detecting early cancer, or a method for diagnosing early cancer, and a diagnostic agent and kit for these methods as follows:

(1) A method for detecting early cancer, comprising:

a) measuring midkine, and/or a fragment thereof, in a biological sample, and,

b) comparing the measured level obtained in step a) to a measured level a healthy subject.

(2) The method according to (1), wherein the early cancer is gastric cancer.

(3) The method according to (2), wherein the gastric cancer is at stage I.

(4) The method according to (1), wherein the early cancer is hepatocellular carcinoma.

(5) The method according to (4), wherein the hepatocellular carcinoma is at stage I.

(6) The method according to (1), wherein the early cancer is lung cancer.

(7) The method according to (6), wherein the lung cancer is at stage I.

(8) The method according to (1), wherein the biological sample is serum or urine.

(9) A use of an antibody recognizing midkine, and/or a fragment thereof, for early cancer detection.

(10) A diagnostic agent for early cancer comprising an antibody that recognizes midkine, and/or a fragment thereof.

(11) A kit for detecting early cancer in a biological sample, wherein

the kit (a) comprises a container that holds an antibody that specifically binds to at least one epitope of midkine, and/or a fragment thereof, and (b) determines the presence of midkine, and/or a fragment thereof in the biological sample.

5 (12) The kit according to (11), wherein the antibody is adsorbed onto a solid.

(13) A method for assessing cancer prognosis, comprising:

- a) measuring midkine, and/or a fragment thereof, in a biological sample, and,
- 10 b) correlating the measured level obtained from step a) to cancer prognosis.

(14) The method according to (13), wherein the cancer is gastric cancer, hepatocellular carcinoma, or lung cancer.

15 Definitions

Unless stated otherwise, the following terms used in this description have the following meanings.

"Early cancer" refers to tumors confined to the site of development (intramucosal) that have not invaded surrounding
20 tissues, or those that have invaded, but the range of invasion is confined to a local area. Especially, tumors showing no invasion are important detection targets in the present invention since they have been difficult to detect by well-known tumor markers. This definition is applicable to almost all cancers such as those of the
25 skin, oral cavity, respiratory tract, gastrointestinal tract, uterine cervix, ovary, gallbladder, bladder, and such. Early cancer includes stage 0 (carcinoma in situ) and stage I according to the TNM classification. In these cancer stages, there are no intravascular invasions or distant metastases, and local tumor
30 ablation alone will lead to complete recovery.

In the present invention, "tumor marker" is defined as a substance produced by tumor cells or cells reacting to tumor cells, which is found in tissues, body fluids, excrements, and such, that can indicate some feature of the tumor, such as its existence,
35 character, or expansion.

The term "MK" includes a full-length MK protein, and a fragment

comprising an amino acid sequence of an arbitrary length having the biological activity of MK. Also included are mutant MK, such as a mutant MK lacking the N-domain that is expressed cancer-specifically (Kaname T. et al.: Biochem. Biophys. Res. Commun., 219: 256-260, 1996. MK produced by genetic engineering technology, and chemically synthesized MK are used interchangeably in this description. A DNA sequence encoding the human full-length MK is well known (U.S. Patent No: 5,461,029). Biological activities of MK not only include the physiological action of MK on cells, but also immunological reactivity with an anti-MK antibody.

"Sensitivity" is the ratio of positive measurements in a tumor-existing group, and is also called positivity ratio.

"Specificity" is the ratio of negative measurements in a tumor-non-existing group, and is also called negativity ratio.

"Biological sample" means a sample that can be obtained from an organism. More specifically, it is, for example, blood, serum, urine, other secretions, and such. Among these biological samples, urine is useful as a sample with low invasiveness. Since urine volume changes considerably, urine volume correction is desirable for a more accurate comparison of urine component concentrations. Creatinine correction and such are well known methods for correcting urine volume.

"Stage classification" is generally, classification of cancer by progression observable by the naked eye, and TNM classification (tumor-node-metastasis staging) is widely used internationally. The "stage classification" used in the present invention corresponds to the TNM classification ("Rinsho, Byori, Genpatsusei Kangan Toriatsukaikiyaku (Clinical and Pathological Codes for Handling Primary Liver Cancer)": 22p. Nihon Kangangaku Kenkyukai (Liver Cancer Study Group of Japan) edition (3rd revised edition), Kanehara Shuppan, 1992).

Furthermore, in the present invention, "detection of cancer" means judging that cancer exists in a subject's body with a high probability. In contrast to detection, screening is a term indicating tests that especially target an arbitrary group, and intends to narrow down subjects with a strong possibility of having

a cancer. The detection of cancer targeting a particular subject is called diagnosis, whereas screening targets arbitrary groups. In the present invention, screening and diagnosis differ only in their targets, and the cancer detection method of the present invention comprises both.

Since the levels of markers produced by cancer cells in the blood do not differ from their standard values in a healthy subject until the cancer grows to a certain size, early cancer detection by an increase in the level of a serum marker is normally considered to be impossible, as mentioned above.

Since MK is highly expressed at the mRNA and protein levels in pre-cancerous stages of colorectal cancer (Ye C. et al.: Br. J Cancer., 79: 179-183, 1999), blood MK levels of patients with various types of cancers were investigated by the present inventors who found that blood MK level was significantly elevated in most patients (87%) compared to healthy subjects. Eighty-seven percent is an extremely high value compared to existing tumor markers. MK expressed in cancer tissues is probably secreted into the bloodstream, and is thought to lead to an increase in blood MK levels. In hepatocellular carcinoma, gastric cancer, lung cancer, and such, blood MK levels rose in the early stages of cancer.

At stage I, blood MK levels in hepatocellular carcinoma or lung cancer patients were already significantly elevated compared to standard values in blood of healthy subjects, and continued to elevate through stages II to IV. In contrast, in stage I gastric cancer patients, the levels were significantly elevated compared to the standard value in healthy subjects, but from stage II and beyond, regardless of the stage, the MK level remained almost the same. Therefore, this showed that detection of early cancer categorized into stage I is possible through measurement of MK in a wide variety of cancers including hepatocellular carcinoma, lung cancer, or gastric cancer. Furthermore, MK measurement allows detection of not only early cancer, but also cancer at various stages, irrespective of cancer expansion and MK accumulation. This feature is important for tumor markers, because tumor makers found only during early cancer will lead to the risk of overlooking progressed

cancer.

The utility of tumor markers are generally evaluated by their "sensitivity" that determines whether a cancer patient is positive, and by their "specificity" that determines whether a non-cancer patient is negative. However, each of the well-known tumor markers has limitations in sensitivity and selectivity.

With MK, its level in blood and urine rises at an early stage compared to the standard level in healthy subjects of various unspecified types of cancers as described in the Examples. This may mean that MK has a wide spectrum of specificity in unspecified types of cancers, and has a high sensitivity. For broad screening of early cancer regardless of the type of organ, high detection sensitivity and specificity towards a specified type of cancer, as well as a wide spectrum of specificity in the detection of unspecified types of cancers are desired. MK is considered to be equipped with such a sensitivity and specificity necessary for screening.

Furthermore, the early cancer detection method based on the present invention augments the limitations in sensitivity and specificity of known tumor markers. It is known that combinations of multiple tumor markers may enable elevation of sensitivity while maintaining invariable specificity. A screening method, that combines multiple tumor markers leading to improved sensitivity and specificity is generally called a combination assay.

In the present invention, early stage detection of the presence of various types of malignant tumors can be detected by measuring MK levels in blood and urine of subjects by EIA and such, through screenings performed on symptomless subjects. Furthermore, sensitivity and specificity may be raised by combining measurements of other tumor markers.

Two points should be considered when performing combination assays. The first point concerns the selection of a tumor marker combination. Once the tumor marker combination is decided, the next consideration concerns how to set its cut-off value.

The essence of tumor marker selection is selecting a combination having the lowest possible correlation to each other.

For example, AFP and PIVKA-II, which are liver tumor markers, have a low correlation, and by taking the PIVKA-II cut-off value at 0.1 Au/ml, they exhibit nearly 100% specificity. Meanwhile, the combination of CA19-9 and CA-50, which are pancreatic cancer markers, yields a combination in which true-positive cases are identical, and false-positive cases do not overlap, making it an inefficient combination.

Once a tumor marker combination is selected, the next step is setting the cut-off value. Cut-off value is an important factor influencing sensitivity and specificity. Generally, sensitivity and specificity of tumor markers are in a trade-off relationship, but those skilled in the art can set an appropriate cut-off value following references (for example, Kawamura, T.: Tumor Marker. Nippon Rinsho 54: 1649-1653, 1996).

In an ideal tumor marker, measurements from the tumor group and the non-tumor group do not overlap, and these measurements can determine the presence of tumors. However, such an ideal tumor marker has not been developed so far. Therefore, a cut-off value most appropriate for distinguishing and differentiating tumor groups and non-tumor groups must be set.

In a preferred embodiment, the cut-off value is the mean value of signals obtained when samples from patients without cancer are incubated with solid phase antibodies. Normally, a sample that generates a three-fold signal than the standard deviation of a predetermined cut-off value is considered to be positive for cancer. Often, the upper and lower limits of the 95% confidence interval (standard range) in the distribution of measured levels for healthy subjects are used as the cut-off values. However, standard ranges are set without any consideration of the distribution of the disease state. Therefore, the cut-off values are preferably determined by clearly defining the disease state to be distinguished by the test, then gathering a constant number of a disease group and non-disease group, testing them, and considering the prevalence rate (the situation where testing is applied) and degree of separation (separability of the test) of the measurements from the two groups. Samples yielding signals with values higher than the cut-off value

determined by this method are considered positive for cancer.

Furthermore, blood MK levels significantly decreased in hepatocellular carcinoma patients after surgically removing the tumor. This shows that MK is useful not only for diagnosis of cancer, but also as an indicator for monitoring the course of the disease, as a prognostic factor, or for monitoring relapse. Prognosis means the response of a patient towards a treatment. Therefore, if a decrease in the MK value is measured before and after tumor treatment, and a decrease in the value is confirmed, one can speculate that the treatment being performed is effective. Furthermore, if the measured MK value decreases to that of a healthy subject, one can speculate that tumor treatment has been successful. Tumor treatment includes radiation therapy, immunotherapy, chemotherapy, and such, besides surgical removal.

In another embodiment, MK can be used as a marker for certain types of cancers, such as hepatocellular carcinoma. Blood MK level rises with the advancement of the stage of hepatocellular carcinoma. For cancer diagnosis, the assay described above is performed multiple times sequentially (over time), and the change in MK level is evaluated. For example, this assay is performed over six months to a year, every twenty-four to seventy-two hours, and is performed thereafter as necessary. Generally, cancer is progressing in patients whose MK value, as detected by antibodies, is increasing sequentially over time.

In the present invention, MK levels within biological samples can be measured by latex agglutination, EIA or RIA method using specific polyclonal or monoclonal antibodies against MK, FIA, chemiluminescence immunoassay, or ECLIA method, and such. Among these, EIA is preferable as an assay for measuring MK in the present invention. Since EIA uses enzymes as labels, EIA can be readily performed compared to RIA that accompanies the problems of half-life and radioactive waste. Further, theoretically, sensitivity of EIA can be enhanced more compared to RIA.

In addition, regarding EIA, various assay systems are known to those skilled in the art (for example, see Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory,

1988). Particularly, an excellent EIA method has been developed (JP-A Hei 10-160735) for MK measurement, and one skilled in the art can improve this well-known method according to detection purposes as necessary.

5 In a related embodiment, assays can be performed by using flow-through or strip test type assay in which an antibody is fixed on to a solid membrane such as nitrocellulose. In the flow-through test type, MK in a sample binds to a solid phased antibody as the sample passes through the membrane. Next, when a solution
10 containing a second antibody passes through the membrane, the labeled second antibody binds to the antibody-polypeptide complex. Next, the bound second antibody is detected as described above. In the strip test type, one end of a membrane with a bound antibody is immersed in a solution containing a sample. The sample shifts
15 through the membrane so as to pass through the region containing the second antibody, and then shifts toward the area of the solid phased antibody. Concentration of the second antibody in the solid phased antibody area indicates the presence of cancer. Typically, concentration of the second antibody in that region causes a pattern
20 such as a line that can be read visually. Absence of such a pattern indicates a negative result. Generally, the amount of antibody fixed onto a solid membrane is selected so as to generate a visually distinguishable pattern. In these cases, the MK level in the biological sample is sufficient to cause a positive signal in a two
25 antibody sandwich assay. The amount of an antibody fixed onto a solid membrane is preferably about 25 ng to 1 μ g, and more preferably about 50 ng to 500 ng. Such tests are normally performed with extremely small amounts of biological samples.

30 In flow-through type or strip test type assay formats, quantitative measurements are possible by automated reading of signal intensities. Alternatively, the sensitivity can be adjusted so that a positive result occurs only when MK is present in a certain concentration or more. Through sensitivity adjustment, positive results can be determined visually without using a special device.
35 The method of adjusting the sensitivity in such types of assay formats is a technology well known to one skilled in the art. For

example, sensitivity can be altered by adjusting the amount of antibodies used.

Of course, many other assay protocols are also suitable for use with the antigens or antibodies of the present invention, and thus those described above are only intended to be examples.

MK antibodies necessary for each type of assay protocol described above, and MK used as standard samples are useful as an early cancer detection kit. An early cancer detection kit according to the present invention comprises at least an anti-MK antibody, and MK used as a standard sample. In addition, the detection kit of the present invention can be combined with an enzyme substrate, negative control, and instructions, and such, necessary for the detection of standard components. When detection kits are used in methods such as EIA, the aforementioned anti-MK antibody can be bound to a solid support beforehand. A reaction vessel, beads, or magnetic particles, and such are generally used as the solid phase. By binding anti-MK antibodies to a solid phase in advance, EIA can be not only performed easily, but also automated.

The anti-MK antibody used in the above-mentioned method can be produced by various techniques well known to one skilled in the art (for example, see Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, 1988). Anti-MK antibodies may be polyclonal or monoclonal antibodies. For example, monoclonal antibodies specifically recognizing MK, such as those according to Japanese Patent Application No. 2000-272199 (applied on September 7, 2000) by the present applicants may be utilized for the present invention. An antibody fragment containing the antigen-binding site may also be used as an anti-MK antibody.. Furthermore, the antibody may be single stranded, chimerized, CDR-grafted, or humanized antibody. The antibody may be produced by the method described herein, or by other methods well known to one skilled in the art.

MK is used as an immunogen for the production of anti-MK antibodies of the present invention, or as standards. MK used for these purposes include biologically derived MK, recombinant MK, or chemosynthetic MK, and furthermore, fragments having biological

activity of MK. The method to obtain MK as a recombinant is well known (JP-A Hei 9-95454).

All prior art publications cited in this description are incorporated herein by reference .

5

Brief Description of the Drawings

Figure 1 shows the result of measuring the serum MK level by one-step sandwich method described in (1) of Example 2, in 76 hepatocellular carcinoma patients at stages I to IV (stage I: 7 patients; stage II: 19 patients; stage III: 23 patients, and stage IV: 27 patients), 7 viral hepatitis patients as a comparative control, and 135 healthy subjects as a control (**p < 0.01). The error bar indicates standard deviation.

Figure 2 similarly shows the result of measuring the serum MK level by one-step sandwich method described in (2) of Example 2, in 76 hepatocellular carcinoma patients at stages I to IV, 7 viral hepatitis patients as a comparative control, and 376 healthy subjects as a control (**p < 0.01, Mann-Whitney U-test). The error bar indicates standard deviation.

Figure 3 similarly shows the result of measuring PIVKA-II level in serum of hepatocellular carcinoma patients at stages I to IV, using Eitest PIVKA-II (Sanko Junyaku Co., Ltd.). The error bar indicates standard error.

Figure 4 is similarly shows the result of measuring AFP level in serum of hepatocellular carcinoma patients at stages I to IV, using α -feto RIA beads (Dainabot) (*p < 0.01). The error bar indicates standard error.

Figure 5 shows the result of measuring the serum MK level by the one-step sandwich method described in (1) of Example 2, in each of 72 gastric cancer patients at stages 1 to 7, and 135 healthy subjects. The error bar indicates standard deviation.

Figure 6 similarly shows the result of measuring serum MK by the one-step sandwich method described in (2) of Example 2 in 72 gastric cancer patients at stages 1 to 7, and 376 healthy subjects (**p < 0.01, Mann-Whitney U-test). The error bar indicates standard deviation.

Figure 7 similarly shows the result of measuring CEA level in the serum of 72 gastric cancer patients at stages 1 to 7 using CEA RIA beads (IRMA method) (Dainabot). The error bar indicates standard error.

Figure 8 similarly shows the result of measuring CA19-9 level in serum in 72 gastric cancer patients at stages 1 to 7 using Centocor CA19-9 Kit (IRMA method) (Centocor). The error bar indicates standard error.

Figure 9 shows the distribution of urine MK level, which were corrected by creatinine values, in 72 cancer patients (gastric cancer: 24 patients; hepatocellular carcinoma: 24 patients; and colon cancer: 24 patients), and 50 healthy subjects ($p < 0.01$; statistics software: StatView-J5.0; using Mann-Whitney U-test).

Figure 10 shows the result of urine MK levels, which were corrected by creatinine values, at stages 1-7 in 3 bile duct cancer, 3 breast cancer, 6 colon cancer, 3 esophageal cancer, 1 gallbladder cancer, 10 hepatocellular carcinoma, 3 pancreatic cancer, 7 rectal cancer, 28 gastric cancer and 1 thyroid cancer patients, 65 patients in total ($*p < 0.05$, $**p < 0.001$). The error bar indicates standard deviation.

Figure 11 shows the effect of hepatocellular carcinoma ablation on MK values in serum. The bar containing dots indicates the value before tumor excision (pre-op), and the solid black bar indicates the value after tumor excision (Day 7).

Figure 12 compares the MK levels in the serum of various types of cancer patients. The thick line indicates the mean value of MK levels in serum of 135 healthy subjects, and the dotted line indicates 0.50 ng/ml cut-off value. The numbers shown below the names of each type of cancer indicate the number of patients, median value, and the 25% to 75% confidence interval. Asterisks indicate a significant difference (Mann-Whitney U-test) compared to a healthy subject. *: $p < 0.05$, **: $p < 0.01$

Best Mode for Carrying out the Invention

The present invention is specifically illustrated below with reference to Examples, but it is not to be construed as being limited

thereto.

[Example 1] Production of anti-human MK polyclonal antibody

5 MK protein used for immunization and recombinant MK protein used as standard material were produced according to the method described in Example 1 of JP-A Hei 9-95454.

10 A cDNA covering the ORF of human MK was introduced into pHIL-D4 expression vector having *Pichia* yeast as its host. This MK expression vector was transfected into *Pichia* yeast G115 (*Pichia pastoris* G115; Research Corporation Technologies). An MK expressing clone was obtained by histidine and G418 selection. MK was purified by ion exchange chromatography and affinity chromatography on a heparin column. The neurotrophic activity of purified MK protein was comparable to that of mouse MK produced by
15 recombinant L-cells.

Immunization injections to rabbits and chickens were carried out every two weeks for six times for rabbits, and every two weeks for 8 times for chickens.

20 Specifically, for rabbits, 400 µg MK mixed with an equivalent amount of Freund's complete adjuvant was initially injected subcutaneously, and from the second time and onwards, 400 µg MK mixed with Freund's incomplete adjuvant was injected each time subcutaneously. For chickens, the procedure was similar to that of rabbits, except that 100 µg MK was used each time for injections.

25 Anti-sera obtained from rabbits were precipitated with ammonium sulfate, then IgG was isolated using a protein A column, and furthermore, this was affinity purified using an MK affinity column in which MK has been immobilized onto Affigel-10™ (BioRad), to yield purified rabbit anti-human MK-specific antibodies. On the
30 other hand, anti-sera obtained from chickens were precipitated with ammonium sulfate, and then affinity purified using an MK affinity column to yield purified chicken anti-human MK-specific antibodies. These antibodies were used for detecting human MK specifically in Western blot analysis.

35

[Example 2] MK measurement by one-step sandwich method

(1) Rabbit anti-human MK antibodies were dissolved (5.5 $\mu\text{g/ml}$) in 50 mM PBS (pH7.2) containing 0.1% NaN_3 , and 50 μl aliquots of this solution were placed into each of the wells of microtiter plates (polysorp plates, Nunc). The plates were maintained at room temperature for 16 hours to adsorb the antibodies onto the wells. After washing with 0.1% Tween 20 in PBS, the wells were blocked by adding 150 μl aliquots of 0.5% bovine serum albumin (BSA) in PBS to each well, and by incubation at 37°C for 2 hours.

On the other hand, 10 μl each of sera at each stage of liver cancer, sera at each stage of gastric cancer, or sera of healthy subjects (control) were reacted with 100 μl peroxidase-labeled chicken anti-human MK antibodies (0.1 $\mu\text{g/ml}$) dissolved with 50 mM Tris-HCl (pH8.4) comprising 0.5 M KCl, 0.5% BSA, and 0.01% Microcide I (aMReSCO, Solon, Ohio). 50 μl aliquots of this reaction solution were added into the wells of the plates, and then incubated at room temperature for 1 hour. Each of the wells was washed 5 times with 1% Tween-20 in PBS. 100 μl aliquots of a substrate solution (0.5mg/ml tetramethylbenzidine) were added into the wells and incubated at room temperature for 30 minutes. The reaction was stopped by adding 2 N H_2SO_4 , and absorbances at 450 nm/ 655 nm were measured using a multiplate reader (Model 3550, BioRad). At the time of measurement, a standard curve was made by measuring known concentrations of MK standard by a similar procedure.

(2) Rabbit anti-human MK antibody dissolving buffer was different from that of (1) mentioned above in that, i) 50 mM Tris-HCl (pH8.1-8.3) was used instead of 50 mM PBS, that the buffer contained 0.15 M NaCl, and the antibody concentration was 5 $\mu\text{g/ml}$; ii) PBS containing 0.1% casein was used as the blocking solution instead of 0.5% BSA; and iii) peroxidase (POD)-labeled chicken anti-human MK antibody dissolving buffer was 50 mM Tris-HCl (pH8.2-8.4) comprising 0.5 M KCl, 0.1% casein, 0.5% BSA, 1 mg/ml rabbit γ -globulin, and 0.01% Microcide I (aMReSCO, Solon, Ohio), and otherwise, MK measurements were carried out by the one-step sandwich method in a manner similar to that in (1) mentioned above.

[Test Example 1] Correlation between each stage of hepatocellular

carcinoma and serum MK levels

(1) Preparation of serum samples

Blood samples were collected from 135 healthy subjects (94 males and 41 females, between ages 21-75), 76 hepatocellular carcinoma (HCC) patients (stage I: 7 patients; stage II: 19 patients; stage III: 23 patients; and stage IV: 27 patients), and as liver disease controls, 7 viral hepatitis patients, 72 adenocarcinoma patients (stage 1: 23 patients; stage 2: 9 patients; stage 3: 7 patients; stage 4: 9 patients; stage 5: 5 patients; stage 6: 9 patients; and stage 7: 10 patients), and then sera were prepared therefrom. The Sera were immediately frozen, and were stored at -20°C until MK measurements.

Thereafter, blood samples were freshly collected from another 376 healthy subjects (152 males and 224 females), and then sera were prepared.

(2) Measurement of serum MK levels

Serum MK levels in each HCC patient, viral hepatitis patient, and 135 healthy subjects were measured by the method according to (1) in Example 2 (Figure 1). The bar in the figure indicates standard deviation. Serum MK levels of HCC patients were confirmed to become significantly higher from stage II compared to those of healthy subjects.

Serum MK levels in each of the above-mentioned HCC patients, viral hepatitis patients, and 376 healthy subjects were measured using the one-step sandwich method according to (2) of Example 2, in which sensitivity of EIA was enhanced (Figure 2). The bar in the figure indicates standard deviation.

Serum MK levels in HCC patients at stage I was 0.22 ng/ml (mean value), a significantly higher value (**p < 0.01; Mann-Whitney test) compared to 0.02 ng/ml (mean value) obtained for healthy subjects. Therefore, MK was found to be extremely useful as a serum tumor marker for early stage HCC.

[Test Example 2] Comparative test with PIVKA-II and AFP in HCC
Currently PIVKA-II and AFP are used widely as HCC tumor markers.

PIVKA-II and AFP are complementary, and combination of PIVKA-II and AFP raises the rate of diagnosis. Therefore, AFP and PIVKA-II were used as comparative control tumor markers.

Serum PIVKA-II was measured using Eitest PIVKA-II (Sanko Junyaku Co., Ltd.) (Figure 3). The assay was EIA. The possibility that HCC is positive from stage III was suggested.

Serum AFP level was measured using α -feto RIA beads (Dainabot) (Figure 4). The assay was immunoradiometric assay (IRMA). AFP was not detected in HCC at stage I, and detection was suggested to be possible from stage II.

That is, early detection of HCC is possible with MK, furthermore, a strong correlation between HCC stage progression and elevation of serum MK concentration was confirmed.

[Test Example 3] Correlation between each stage of gastric cancer and serum MK levels

(1) Preparation of serum samples

Blood samples were collected from 72 gastric cancer patients (stage 1: 23 patients; stage 2: 9 patients; stage 3: 7 patients; stage 4: 9 patients; stage 5: 5 patients; stage 6: 9 patients; and stage 7: 10 patients), and then sera were prepared. The sera were immediately frozen, and were stored at -20°C until MK measurement. The values for serum MK levels of 135 healthy subjects and 376 healthy subjects obtained in Test Example 1 were used, individually.

(2) Measurement of serum MK levels

Serum MK levels in each stage (1-7) of gastric cancer and those of 135 healthy subjects are shown in Figure 5 (the bar in the figure indicates standard deviation), and those of 376 healthy subjects are shown in Figure 6 (**p < 0.01; Mann-Whitney U-test; the bar in the graph indicates standard deviation), individually.

Figure 6 confirmed that serum MK levels in gastric cancer patients are significantly higher than those of healthy subjects from stage 1. That is, MK was found to be useful as a tumor marker for early diagnosis of gastric cancer.

[Test Example 4] Comparative test with CEA and CA19-9 in gastric cancer

CEA and CA19-9 were selected as comparative control tumor markers. Serum CEA levels have been found to rise in various cancers of the digestive organs, as well as in various other cancers, and thus are being widely applied clinically. On the other hand, CA19-9 has been found to indicate highly positive values in cancers of pancreas and biliary system. Currently, CA19-9 along with CEA are the most widely used tumor markers for cancers of digestive organs in routine clinical applications.

Serum MK levels were measured in gastric cancer patients using CEA RIA beads (Dainabot) for serum CEA (Figure 7; the bar in the figure indicates standard deviation). The assay used was IRMA. Although CEA may be determined as positive from stage 7, significant differences between stages could not be confirmed because of large standard deviations between each of the stages.

Serum CA19-9 was measured using Centocor CA19-9 RIA kit (Centocor; normal value: 37 U/ml or less) (Figure 8; the bar in the figure indicates standard error). The assay used was IRMA. CA19-9 indicated high values only at stage 5, and is thus speculated to have no correlation to the stages.

That is, MK was found to be useful as a serum tumor marker for early gastric cancer.

[Test Example 5] Serum MK level in gastric cancer patients and lung cancer patients

Serum MK levels were investigated at the early stages in gastric cancer patients and lung cancer patients (Table 1). Both gastric cancer patients and lung cancer patients indicated mean values of serum MK levels at stage I that were lower than those of stages II to IV, but the differences were not statistically significant in both gastric cancer patients and lung cancer patients.

Table 1 Serum MK levels (ng/ml)

	stage	
	I	II~IV
gastric cancer (n=31)	0.73 (n=18)	0.93 (n=13)
lung cancer (n=21)	1.21 (n=11)	2.05 (n=8)

[Test Example 6] Measurement of urine MK levels in cancer patients

MK levels of 72 urine samples of cancer patients (gastric cancer: 24 patients; hepatocellular carcinoma: 24 patients; and colon cancer: 24 patients), and 50 morning urine samples of healthy subjects taken during health checks were measured by the method in (2) of Example 2. Furthermore, creatinine values were measured in the same urine, and then MK values were corrected with the creatinine values. The results are indicated in Figure 9. A significant difference ($p < 0.01$; using Mann-Whitney U-test) was confirmed between urine MK values of healthy subjects and cancer patients.

[Test Example 7] Correlation between urine MK values in cancer patients and cancer stages

The correlation between urine MK values in cancer patients and cancer stages was investigated. Stage categorizations (stages 1-7) were made on a total of 65 patients comprising 3 bile duct cancer patients, 3 breast cancer patients, 6 colon cancer patients, 3 esophageal cancer patients, 1 gallbladder cancer patient, 10 hepatocellular carcinoma patients, 3 pancreatic cancer patients, 7 rectal cancer patients, 28 gastric cancer patients, and 1 thyroid cancer patient. Then, urine MK levels were measured. MK levels at each stage are shown in Figure 10 as corrected values of urine MK ($*p < 0.05$, $**p < 0.01$; Mann-Whitney U-test). Urine MK levels were found to rise significantly in stage I of cancer compared to healthy subjects. To date, tumor markers in urine that increase during the early stages of cancer have not been reported. That is, urine MK level is useful for early screening of various cancers.

[Test Example 8] Effect of tumor ablation on serum MK level in HCC

The effect of tumor ablation by a surgical operation on serum MK level was investigated for 5 HCC patients (Figure 11). In 4 patients, serum MK level significantly decreased 7 days after tumor ablation. That is, serum MK level reflects the therapeutic effect on HCC.

[Test Example 9] Serum MK level in various cancers

Table 2 itemizes the stages of a total of 150 cancer patients comprising 18 esophageal cancer patients, 30 gastric cancer patients, 2 duodenal cancer patients, 25 colorectal cancer patients, 25 hepatocellular carcinoma patients, 12 bile duct cancer and gallbladder cancer patients, 9 pancreatic cancer patients, 5 thyroid cancer patients, 19 lung cancer patients, and 5 breast cancer patients. The result of measuring the serum MK levels of these 150 cancer patients by EIA is indicated in Figure 12. Serum MK levels of 150 cancer patients indicated significant difference to those of healthy subjects ($p < 0.001$, Mann-Whitney U-test). Serum MK levels larger than the 0.5 ng/ml cut-off value was seen in 87% of the patients.

Table 2

	0	I	II	III	IV	relapse
esophageal cancer		5	4	6	2	
gastric cancer		18	2	6	4	
duodenal cancer		0	0	2	0	
colon cancer	1	4	4	5	5	6
hepatocellular carcinoma		0	11	9	2	3
bile duct and gallbladder cancer		2	4	4	2	
pancreatic cancer		5	0	1	3	
thyroid cancer		0	4	1	0	

lung cancer		11	1	6	1	
breast cancer	0		3	0	1	

Industrial Applicability

5 This invention provides a tumor marker useful for diagnosing early cancer. The tumor marker is useful for screening early cancer, estimating the stage and prognosis of certain types of cancers, and for monitoring the course of treatment.

CLAIMS

1. A method for detecting early cancer, comprising:
 - a) measuring midkine, and/or a fragment thereof, in a biological sample, and,
 - b) comparing the measured level obtained in step a) to a measured level a healthy subject.
2. The method according to claim 1, wherein the early cancer is gastric cancer.
3. The method according to claim 2, wherein the gastric cancer is at stage I.
4. The method according to claim 1, wherein the early cancer is hepatocellular carcinoma.
5. The method according to claim 4, wherein the hepatocellular carcinoma is at stage I.
6. The method according to claim 1, wherein the early cancer is lung cancer.
7. The method according to claim 6, wherein the lung cancer is at stage I.
8. The method according to claim 1, wherein the biological sample is serum or urine.
9. [A use of] an antibody [recognizing] midkine, [and/or] a fragment thereof, [for early cancer detection].
10. A diagnostic agent for early cancer comprising an antibody that recognizes midkine, and/or a fragment thereof.
11. A kit for detecting early cancer in a biological sample, wherein

the kit (a) comprises a container that holds an antibody that specifically binds to at least one epitope of midkine, and/or a fragment thereof, and (b) determines the presence of midkine, and/or a fragment thereof in the biological sample.

5

12. The kit according to claim 11, wherein the antibody is adsorbed onto a solid.

13. A method for assessing cancer prognosis, comprising:

- 10 a) measuring midkine, and/or a fragment thereof, in a biological sample, and,
 b) correlating the measured level obtained from step a) to cancer prognosis.

15 14. The method according to claim 13, wherein the cancer is gastric cancer, hepatocellular carcinoma, or lung cancer.

20

A

ABSTRACT

5 MK (midkine) was found to rise in the blood or urine of patients
with various types of cancers at early stage. Based on this finding,
a method for detecting early cancer, comprising the step of measuring
MK in blood or urine was completed.

1/12




FIG. 1

2/12




FIG. 2

3/12




FIG. 3

4/12




FIG. 4

5/12




FIG. 5

6/12




FIG. 6

7/12




FIG. 7

8/12




FIG. 8

9/12




FIG. 9

10/12




FIG. 10

11/12




FIG. 11

12/12




FIG. 12

Docket No. SPO-116

DECLARATION (37 C.F.R. § 1.63) AND POWER OF ATTORNEY

As a below-named inventor, I hereby declare that:

My residence, post office address, and citizenship are as stated below next to my name; and

I believe that I am the original, first, and sole inventor (if only one name is listed below), or an original, first, and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled **EARLY CANCER TUMOR MARKER**, specification for which

☐ is attached hereto.

☒ was filed March 8, 2002, Serial No. 10/070,569.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the patentability of this application in accordance with Title 37, Code of Federal Regulations, § 1.56 (a).

I hereby claim foreign priority benefits under Title 35, United States Code §119 and/or §365 of any foreign application(s) for patent or inventor's certificate listed below and have also identified any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Application Serial No.	Country	Filing Date	Priority Claimed
11/256678	JP	September 10, 1999	Yes
11/345404	JP	December 3, 1999	Yes
2000/33168	JP	February 10, 2000	Yes

I hereby claim priority benefits under Title 35, United States Code §119 of any provisional application(s) for patent listed below:

Application Serial No.	Filing Date	Priority Claimed
---------------------------	-------------	------------------

I hereby claim the benefit under Title 35, United States Code, §120 and/or §365 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application(s) in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which became available between the filing date of the prior application and the national or PCT international filing date of this application:

Application Serial No.	Filing Date	Status (Patented, Pending, Abandoned)
PCT/JP00/06147	September 8, 2000	Pending

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Docket No. SPO-116

I hereby appoint the following persons registered to practice before the Patent and Trademark Office as my attorneys with full power of substitution and revocation to prosecute this application and all divisions and continuations thereof and to transact all business in the Patent and Trademark Office connected therewith: David R. Saliwanchik, Reg. No. 31,794; Jeff Lloyd, Reg. No. 35,589; Doran R. Pace, Reg. No. 38,261; Christine Q. McLeod, Reg. No. 36,213; Jay M. Sanders, Reg. No. 39,355; Jean Kyle, Reg. No. 36,987; James S. Parker, Reg. No. 40,119; Frank C. Eisenschenk, Reg. No. 45,332; Seth Blum, Reg. No. 45,489; Glenn P. Ladwig, Reg. No. 46,853; Margaret Efron, Reg. No. 47,545; and Jon Michael Gibbs, Reg. No. 47,594.

I request that all correspondence be sent to: ~~Customer No.~~ 23557

David R. Saliwanchik
Saliwanchik, Lloyd & Saliwanchik
A Professional Association
2421 N.W. 41st Street, Suite A-1
Gainesville, FL 32606-6669

I further request that all telephone communications be directed to:

David R. Saliwanchik
352-375-8100

1 - ∞ Name of First or Sole Inventor Takashi Muramatsu

Residence Aichi, Japan J P X Citizenship Japan

Post Office Address 2845-161, Aza Kuroishi, Oaza Hirabari, Tenpaku-cho, Tenpaku-ku,

Nagoya-shi, Aichi 468-0021 Japan

Takashi Muramatsu
Signature of First or Sole Inventor

Date June 20, 2002

2 - ∞ Name of Second or Joint Inventor Kohji Okamoto

Residence Fukuoka, Japan J P X Citizenship Japan

Post Office Address 3-18-13-502, Aoyama, Yahata-nishiku, Kitakyushu-shi,

Fukuoka 806-0043 Japan

Kohji Okamoto
Signature of Second or Joint Inventor

Date July 2nd, 2002

3 - ∞ Name of Third or Joint Inventor Shinya Ikematsu

Residence Kanagawa, Japan J P X Citizenship Japan

Post Office Address c/o Meiji Dairies Corporation, Pharmaceutical Department,

540, Naruda, Odawara-shi, Kanagawa 250-0862 Japan

Shinya Ikematsu
Signature of Third or Joint Inventor

Date June 25, 2002

4-00 Name of Fourth or Joint Inventor Munehiro Oda

Residence Kanagawa, Japan ☒ JPX Citizenship Japan

Post Office Address c/o Meiji Dairies Corporation, Food Functionality Research Institute

540, Naruda, Odawara-shi, Kanagawa 250-0862 Japan

Munehiro Oda
Signature of Fourth or Joint Inventor

Date Jun 25, 2002

5-00 Name of Fifth or Joint Inventor Hideshi Kumai

Residence Kanagawa, Japan ☒ JPX Citizenship Japan

Post Office Address c/o Meiji Dairies Corporation

540, Naruda, Odawara-shi, Kanagawa 250-0862 Japan

Hideshi Kumai
Signature of Fifth or Joint Inventor

Date June 25, 2002

6-00 Name of Sixth or Joint Inventor Sadatoshi Sakuma

Residence Tokyo, Japan ☒ JPX Citizenship Japan

Post Office Address c/o Cell Signals. Corp.

Iwata-Bil., 11, Konya-cho, Kanda, Chiyoda-ku, Tokyo 101-0035 Japan

Sadatoshi Sakuma
Signature of Sixth or Joint Inventor

Date Jun 25, 2002